Posted by Michael Wonder on 10 Oct 2023
ImmPACT Bio granted FDA fast track designation for IMPT-514 for the treatment of both active, refractory lupus nephritis and systemic lupus erythematosus
10 October 2023 - IMPT-514 is the first CD19/CD20 CAR T-cell therapy in development for lupus.
ImmPACT Bi today announced the US FDA has granted fast track designation for IMPT-514, a potential first in class CD19/CD20 CAR-T therapy for the treatment of patients with active refractory lupus nephritis and systemic lupus erythematosus.
